Evaluation, for Patients Requiring a Liver Cancer Surgery, of the Use of Fluorescence Imaging Device: Faisability and Efficiency of Lesional and/or Anatomical Marking
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
First step: assess the feasibility and the acceptability of Fluobeam
The ability to detect fluorescence The ability to investigate the mobilized parenchyma The ability to use the medical device following requested asepsis procedures Surgeon satisfaction Nurse satisfaction
During surgery on day 0
No
Patrice Peyrat
Principal Investigator
Centre Léon Bérard, LYON, FRANCE.
France: Agence Nationale de Sécurité du Médicament et des produits de santé
HEPATOFLUO
NCT01738217
January 2013
August 2014
Name | Location |
---|